Since the beginning of the pandemic, governments have spent at least €93 billion on Covid-19 vaccines and therapeutics globally. But, which interests were defended? Those of profit, or those of public health?
To answer this question, The Left in the European Parliament has commissioned a study analysing the agreements between pharma companies and the European Commission and other institutions. The study carried out by Medicine Law & Policy, a research group working in the public interest, analyses five contracts: EU-AstraZeneca, EU-CureVac, EU-Moderna, UK-AstraZeneca, and US-Moderna. Although most of the documents are heavily redacted, the comparative analysis allows drawing important conclusions and it shows that the European Commission was not able – unlike other institutions – to secure advantageous clauses.
Thursday, 15. July 2021
13:00 – 14:30 (CET)
via Zoom
For further information, see the website of The Left in the European Parliament (formerly GUE/NGL)
Programme
Welcome and opening remarks
Silvia Modig MEP, ENVI Coordinator for the Left
Presentation of the study by the author
Ellen t’Hoen LLM PHD, Researcher, MLP
Intervention
Olivier Hoedman, Research and Campaign coordinator, CEO
Intervention
Yannis Natsis, Policy manager, EPHA
Discussion with participants
Conclusions
Kateřina Konečná MEP, The Left group health expert